Pneumococcal vaccine for preventing Streptococcus pneumoniae infection in HIV-positive individuals

2021 ◽  
Vol 2021 (12) ◽  
Author(s):  
Corinna Sadlier ◽  
Kathleen Bennett ◽  
Anne Matthews ◽  
David Mockler ◽  
Fiona Wilson ◽  
...  
Blood ◽  
1979 ◽  
Vol 54 (5) ◽  
pp. 1171-1175 ◽  
Author(s):  
AM Levine ◽  
GD Overturf ◽  
RF Field ◽  
D Holdorf ◽  
A Paganini-Hill ◽  
...  

Abstract Fulminant bacterial sepsis has been described in patients with Hodgkin disease who have undergone splenectomy for staging purposes. The organisms commonly associated with sepsis in this setting include Streptococcus pneumoniae and Haemophilus influenzae. Polyvalent pneumococcal vaccine (Merck) has recently been licensed and has been suggested for use in patients with Hodgkin disease who are at risk for postsplenectomy sepsis. We administered 14-valent pneumococcal vaccine to 24 patients with Hodgkin disease and 24 normal controls, and measured antibody response to 13 antigens at time of immunization and at 3 wk and 3 mo following immunization. Our results indicate that patients who have been previously treated for Hodgkin disease, with chemotherapy, radiotherapy, or both, have severe impairment of antibody response. Untreated patients, however, respond in a manner similar to normal controls.


2016 ◽  
Vol 4 (1) ◽  
Author(s):  
Parham Sendi ◽  
Eva Maria Moser Schaub ◽  
Konstantinos Nirgianakis ◽  
Lucy J. Hathaway ◽  
Pascal Bittel ◽  
...  

Abstract This report describes a case of relapsing pneumococcal peritonitis. The postulated source of infection was vaginal colonization and secondary adherence of pneumococci to an intrauterine contraceptive device. After immunization with a conjugate pneumococcal vaccine, her antibody levels were observed. She remained infection free at the 2-year follow-up investigation.


2015 ◽  
Vol 64 (7) ◽  
pp. 795-797 ◽  
Author(s):  
Silvia Baroncelli ◽  
Clementina Maria Galluzzo ◽  
Giuseppe Liotta ◽  
Mauro Andreotti ◽  
Haswell Jere ◽  
...  

mSphere ◽  
2020 ◽  
Vol 5 (2) ◽  
Author(s):  
Moon H. Nahm ◽  
Jigui Yu ◽  
Jiri Vlach ◽  
Maor Bar-Peled

ABSTRACT We are exposed daily to many glycans from bacteria and food plants. Bacterial glycans are generally antigenic and elicit antibody responses. It is unclear if food glycans’ sharing of antigens with bacterial glycans influences our immune responses to bacteria. We studied 14 different plant foods for cross-reactivity with monoclonal antibodies (MAbs) against 24 pneumococcal serotypes which commonly cause infections and are included in pneumococcal vaccines. Serotype 15B-specific MAb cross-reacts with fruit peels, and serotype 10A MAb cross-reacts with many natural and processed plant foods. The serotype 10A cross-reactive epitope is 1,6-β-galactosidase [βGal(1-6)], present in the rhamno-galacturonan I (RG-I) domain of pectin. Despite wide consumption of pectin, the immune response to 10A is comparable to the responses to other serotypes. An antipectin antibody can opsonize serotype 10A pneumococci, and the shared βGal(1-6) may be useful as a simple vaccine against 10A. Impact of food glycans should be considered in host-pathogen interactions and future vaccine designs. IMPORTANCE The impact of food consumption on vaccine responses is unknown. Streptococcus pneumoniae (the pneumococcus) is an important human pathogen, and its polysaccharide capsule is used as a vaccine. We show that capsule type 10A in a pneumococcal vaccine shares an antigenic epitope, βGal(1-6), with pectin, which is in many plant foods and is widely consumed. Immune response to 10A is comparable to that seen with other capsule types, and pectin ingestion may have little impact on vaccine responses. However, antibody to pectin can kill serotype 10A pneumococci and this shared epitope may be considered in pneumococcal vaccine designs.


2005 ◽  
Vol 24 (4) ◽  
pp. 320-323 ◽  
Author(s):  
Richard I. Haddy ◽  
Kelvin Perry ◽  
Chris E. Chacko ◽  
William B. Helton ◽  
Mark G. Bowling ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document